The ability of Mylan to raise EpiPen’s list price by nearly 550% over the past eight years underscores the pricing power drug companies enjoy for iconic brands facing little competition.
WSJ.com: What's News US, Wall Street Journal
Thu, 08/25/2016 - 1:49pm
The ability of Mylan to raise EpiPen’s list price by nearly 550% over the past eight years underscores the pricing power drug companies enjoy for iconic brands facing little competition.